(Circulation. 2000;102:1542.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Cardiac Dysfunction and Mortality in HIV-Infected Children
The Prospective P2C2 HIV Multicenter Study
From the Division of Pediatric Cardiology (S.E.L.), University of Rochester Medical Center and Children’s Hospital at Strong and Department of Pediatrics (S.E.L.), University of Rochester School of Medicine and Dentistry, Rochester, NY; Department of Cardiology (S.E.L., S.D.C.), Children’s Hospital, Department of Pediatrics, Harvard Medical School (S.E.L., S.D.C.), Department of Pediatrics, Boston Medical Center and Boston University School of Medicine (S.E.L.), and Department of Medicine, Brigham and Woman’s Hospital (E.J.O.), Boston, Mass; Department of Biostatistics and Epidemiology (K.A.E.) and Department of Pediatrics, Division of Pediatric Cardiology (D.S.M.), Cleveland Clinic Foundation, Cleveland, Ohio; Department of Pediatrics, Division of Pediatric Cardiology, University of California, Los Angeles Medical Center and School of Medicine, Los Angeles (S.K.); Department of Pediatrics, Division of Pediatric Cardiology, Mt Sinai School of Medicine (W.W.L.), and Department of Pediatrics, Division of Pediatric Cardiology, Presbyterian Hospital/Columbia University College of Physicians and Surgeons (T.J.S.), New York, NY; Department of Pediatrics, Division of Pediatric Cardiology, Baylor College of Medicine, Houston, Tex (J.T.B.); and the National Heart, Lung, and Blood Institute, Bethesda, Md (G.S.).
Correspondence to Dr Steven E. Lipshultz, Division of Pediatric Cardiology, University of Rochester Medical Center, 601 Elmwood Ave, Box 631, Rochester, NY 14642. E-mail steve_lipshultz{at}urmc.rochester.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Left ventricular (LV) dysfunction is common in children infected with the human immunodeficiency virus (HIV), but its clinical importance is unclear. Our objective was to determine whether abnormalities of LV structure and function independently predict all-cause mortality in HIV-infected children.
Methods and Results—Baseline echocardiograms were obtained on 193
children with vertically transmitted HIV infection (median age, 2.1
years). Children were followed up for a median of 5 years. Cox
regression was used to identify measures of LV structure and function
predictive of mortality after adjustment for other important
demographic and baseline clinical risk factors. The time course of
cardiac variables before mortality was also examined. The 5-year
cumulative survival was 64%. Mortality was higher in children who, at
baseline, had depressed LV fractional shortening (FS) or
contractility; increased LV dimension, thickness, mass,
or wall stress; or increased heart rate or blood pressure
(P
0.02 for each). Decreased LV FS
(P<0.001) and increased wall thickness
(P=0.004) were also predictive of increased mortality
after adjustment for CD4 count (P<0.001), clinical
center (P<0.001), and encephalopathy
(P<0.001). FS showed abnormalities for up to 3 years
before death, whereas wall thickness identified a population at risk
only 18 to 24 months before death.
Conclusions—Depressed LV FS and increased wall thickness are risk factors for mortality in HIV-infected children independent of depressed CD4 cell count and neurological disease. FS may be useful as a long-term predictor and wall thickness as a short-term predictor of mortality.
Key Words: viruses • mortality • pediatrics • AIDS
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Children infected with the human immunodeficiency virus (HIV) may develop a wide range of cardiovascular abnormalities, some of which are known to be associated with poor survival.1 2 3 In addition, we recently reported that among HIV-infected children, baseline echocardiographic abnormalities are common, persistent, and often progressive.1
To determine the clinical value of baseline echocardiographic findings as predictors of mortality, we studied children with vertically transmitted HIV infection participating in a National Heart, Lung, and Blood Institute study, Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV). We examined 9 echocardiographic measures of left ventricular (LV) structure and function at enrollment to determine whether any abnormalities predicted mortality after adjustment for demographic variables and other risk factors. We also constructed longitudinal profiles of the echocardiographic measurements to determine how early the predictors could distinguish between survivors and nonsurvivors.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We have previously described the P2C2 HIV study, a natural history study of cardiac and pulmonary complications of vertically transmitted HIV infection at 5 clinical centers (10 hospitals) in different parts of the United States.4 Although 2 prospective cohorts of HIV-infected children were included in the study design, this report is limited to the older HIV-infected cohort (group 1). Briefly, 205 group 1 children >28 days old with documented maternally transmitted HIV infection were enrolled between May 1990 and April 1993. Recruitment of patients occurred in pediatric clinics (hospital-based and non–hospital-based) and inpatient wards, resulting in a sequential enrollment of all consenting patients. The protocol was approved by the institutional review board at each center. Informed consent was obtained from the patient, the parent, or the legal guardian. Patient interval histories were obtained during visits to the clinic or retrospectively from medical records. The other prospective cohort consisted of 600 infants born to HIV-infected mothers enrolled during pregnancy or before 28 days postpartum. They are not included in the present article because the covariates measured at birth are very different from those measured in a cohort of patients who enroll at later ages and are mostly symptomatic.
All children underwent protocol-directed echocardiographic testing every 4 months regardless of clinical status using Hewlett Packard 500, 1000, 1500, and Acuson 128 XP equipment. All echocardiograms were centrally remeasured by 1 of 3 technicians unaware of the clinical status of the patient. For each echocardiographic study, children <4 years old were sedated if necessary. 2D echocardiography and Doppler studies with stress-velocity analysis were performed for each child.1 Afterload was measured as meridional end-systolic LV wall stress. LV mass was calculated from the M-mode measurements by the method of Devereux et al.5
Normative values for the echocardiographic measures according to age or body surface area were developed from 285 healthy children (these external control subjects were not part of the P2C2 HIV study) measured at the same central interpretation unit in the same manner as the patients.1 To adjust for growth, z scores were created for the HIV-infected children by taking each echocardiographic measure, subtracting the age-appropriate or body surface area–appropriate mean, and dividing by 1 SD. Therefore, a z score of 0 represents a measurement equal to the normal mean value for the child’s age or body surface area, whereas a z score of -2 represents a measurement 2 SD below average. Age correction was used for fractional shortening (FS), wall stresses, blood pressure, and heart rate; body surface area correction was used for LV dimension, end-diastolic posterior wall thickness, and mass.1
The prognostic variables were measured at the time of the initial
echocardiogram. Covariates were chosen because of prior work suggesting
that they were important for cardiovascular morbidity
and mortality.1 2 3 Baseline covariates were sex, race,
clinical center, CD4 cell count z score, height and weight
z scores,6 CDC HIV-disease stage,
encephalopathy, a diagnosis of Pneumocystis carinii
pneumonia, chest radiographic findings, any zidovudine
exposure, and age at initial echocardiogram. Baseline measures of
cardiac function were FS, end-diastolic dimension,
end-systolic dimension, heart rate, LV mass,
end-systolic wall stress (afterload), wall thickness,
contractility, and diastolic blood
pressure. Each of the echocardiographic
parameters was dichotomized at 
2 SD except FS (-2 SD),
contractility (-2 SD), and wall thickness (1 SD
because too few children exceeded 2 SD). An abnormal chest radiograph
was defined by the presence of nodular densities, reticular densities,
parenchymal consolidation, or increased bronchovascular markings. These
radiographs were read with a standardized tool7 at
each center by a pediatric radiologist unaware of the child’s clinical
status. CD4 lymphocyte counts were determined from the first available
reading within 6 months of the initial echocardiogram at laboratories
using AIDS Clinical Trials Group quality assurance protocols.
z scores were determined for CD4 counts8
and for height and weight6 and were categorized as either
-2 or >-2. Serum was analyzed for HIV-1 RNA concentration
by quantitative HIV-1 RNA polymerase chain reaction.9 The
1994 revised CDC classification system10 was used to
classify each child according to the most severe clinical HIV stage up
to the time of first echocardiogram.
Statistical Analyses
Cumulative survival was estimated with the Kaplan-Meier method.
Log-rank tests were used to compare survival according to baseline
clinical characteristics and baseline measures of cardiac function,
with groups defined by dichotomized z scores. Relative risks
were calculated to measure the degree of association between the
baseline cardiac function z scores and survival by fitting
the Cox proportional-hazards regression model separately for each
baseline echocardiographic measurement. The Spearman
rank-order correlation coefficient was used to determine the
association between echocardiographic
parameters. All tests were 2-sided and unadjusted for
multiple comparisons. A value of P<0.05 indicated
statistical significance.
Forward and backward stepwise selection were used to choose prognostic variables for a Cox proportional-hazards regression model, and both methods led to the same results. Only factors that were significant at P<0.05 in the univariable analyses were included in the multivariable analyses. The relative risk and its 95% CI were calculated for each factor in the presence of others in the final model.
Repeated-measures analyses were performed for each cardiac function measurement and z score to examine the amount of time before death that a predictor could discriminate children who died from those who were still alive at the end of follow-up. For each cardiac outcome, these analyses performed by SAS Proc Mixed provided separate estimates of the mean and 95% CIs according to vital status and time before the last echocardiogram or death.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patient Population
Of the 205 enrolled children, a central analysis of echocardiographic data was performed for 193 children, who constitute the study cohort. The remaining 12 children were not included because of inability to centrally remeasure the initial echocardiogram (5 children, of whom 4 died and 1 was lost to follow-up), 1 large atrial septal defect, pulmonary hypertension and wall motion abnormalities (2 children, 1 of whom died), and absence of an echocardiogram (4 children, of whom 2 died and 2 were lost to follow-up).
Most of the children were black (86 children) or Hispanic (73
children), and only 22 children were asymptomatic before
the initial echocardiogram. The median age at the first echocardiogram
was 2.1 years and the median CD4 cell count was
690/mm3 (median z score, -1.92 SD;
the normal CD4 cell count for a 2-year-old was
2298/mm3).8 Table 1
shows the cumulative survival,
with 64 of the 193 study children dying. The overall 5-year survival
was 64% (95% CI, 56.6% to 71.3%). The median length of follow-up
for the 129 children alive at last contact was 60 months. Of the 27
lost to follow-up, additional data on vital status were obtained for 21
children.
|
Univariable Predictors of Mortality
Survival was not affected by race or ethnicity, sex, age category
(0 to 1, 1 to 2, 2 to 4, >4 years), or chest radiograph findings
(Table 1
). However, when a Cox model was used with the actual
noncategorized age, the association between age and mortality was
significant (P=0.02). Survival was lower for children who
were short for age (P<0.001) or underweight for age
(P<0.001) at baseline. The presence of encephalopathy and
increasing severity of CDC symptoms at baseline were both associated
with higher mortality (P<0.001). Survival also differed
among clinical centers (P=0.02). Other factors associated
with lower cumulative survival included suppressed CD4 cell counts
(P<0.001), a history of zidovudine therapy
(P=0.03), and Pneumocystis carinii pneumonia
diagnosed before the initial echocardiogram (P=0.02).
The relationship between mortality and baseline impaired cardiac
function is shown in Table 2 and Figure 1. Mortality was higher in children with
a depressed baseline FS (P<0.001). A similar pattern was
noted for contractility (P=0.01). Mortality
was also significantly higher for children with increased
end-diastolic dimension (P<0.001),
end-systolic dimension (P<0.001), wall stress
(P=0.002), heart rate (P=0.006), LV mass
(P<0.001), end-diastolic posterior wall
thickness (P=0.02 for 1 SD), or diastolic
blood pressure (P=0.003).
|
|
Figure 1 illustrates the impact on cumulative survival of each
of the clinical and echocardiographic measures that are
also significant in the multivariable models described below.
Alternative analyses using Cox proportional-hazards models
separately for each echocardiographic measure as a
continuous z score produced similar results. An increased
risk of death per 1 SD change in z score occurred with
increased LV mass (relative risk, 1.84; P<0.001), increased
end-diastolic dimension (relative risk, 1.69;
P<0.001), increased end-systolic dimension
(relative risk, 1.68; P<0.001), decreased FS (relative
risk, 1.39; P<0.001), increased heart rate (relative risk,
1.34; P=0.001), increased wall thickness (relative risk,
1.29; P=0.009), depressed contractility
(relative risk, 1.30; P<0.001), and increased afterload
(relative risk, 1.25; P<0.001). Survival was not affected
by baseline diastolic blood-pressure z scores
when analyzed as a continuous variable
(P=0.31).
Statistically significant associations were found between FS and
contractility (
=0.56), end-diastolic
dimension (=-0.31), end-systolic dimension (=-0.61),
afterload (=-0.63), and LV mass (=-0.31) at baseline. Wall
thickness and LV mass were also closely correlated at baseline
(=0.45).
Multivariable Predictors of Mortality
Data were available for all covariates in 184 children (9 children
who did not have a CD4 cell count within 6 months of the baseline
echocardiogram could not be included in the analyses). A
multivariable Cox model using stepwise selection was used to
identify a subset of covariates as independent risk factors for
survival. CD4 count z score, clinical center,
encephalopathy, and age at initial echocardiography
remained significantly associated with survival. Factors that did not
remain significant included zidovudine exposure, P carinii
pneumonia, and continuous-weight z score.
After these significant nonechocardiographic covariates had been included, the Cox model was refitted separately for each echocardiographic z score. FS (P<0.001), contractility (P<0.001), end-systolic dimension (P<0.001), LV wall thickness (P=0.008), and LV mass (P=0.007) remained significant. Heart rate, afterload, and end-diastolic dimension lost significance after adjustment for nonechocardiographic covariates.
In the final model in Table 3, both
decreased FS z score (P<0.001) and increased
wall thickness z score (P=0.004) were independent
prognostic risk factors of mortality after adjustment for CD4 count
z score (P<0.001), encephalopathy
(P<0.001), and clinical center (center 1 versus center 5,
P<0.001; center 3 versus center 5, P=0.03). The
adjusted relative risk for FS was 1.31 per 1 SD drop, and for wall
thickness was 1.35 per 1 SD increase. Age, LV mass,
contractility, and dimension lost significance and were
not retained in the model. Because LV mass and wall thickness were
highly correlated, the model was also fitted with LV mass instead of
wall thickness; both FS (P<0.001) and LV mass
(P=0.04) were independently associated with survival after
adjustment for CD4 count, encephalopathy, and clinical center.
Likewise, the model was also fitted with LV
contractility instead of FS; both wall thickness
(P=0.02) and contractility
(P=0.006) were independently associated with survival after
adjustment for CD4 count, encephalopathy, and clinical center.
|
High FS or contractility and low LV mass were found not to be risk factors for death. However, we did find an additive relationship between LV wall thickness and dimension. Cumulative 5-year survival for the 18 children with elevated (>1 SD) ventricular dimension and elevated (>0.5 SD) wall thickness was 22.5%. In contrast, survival among the 100 children with normal dimension and thickness was 76.2% (P<0.001). Five-year survival was 64.2% among 40 children with only increased thickness and 51.7% among 35 children with only increased dimension.
In a subset of 157 patients for whom HIV RNA copy number was available, decreased FS and increased wall thickness z scores still remained significant predictors of mortality after adjustment for HIV RNA copy number (analyzed on a logarithmic base 10 scale) (P=0.04), CD4 cell count z score (P<0.001), encephalopathy (P<0.001), and clinical center (center 1 versus center 5, P<0.001; center 3 versus center 5, P=0.02). The relative risk was 1.39 per 1 SD increase (P=0.004) for wall thickness and 1.41 per 1 SD decrease (P<0.001) for FS. Replacing wall thickness z score with LV mass z score provided similar findings.
Timing of Mortality
Figure 2 shows the model-based means
and 95% CIs for measurements and z scores according to time
before the last echocardiogram or death for the 64 children who died
and the 129 children who remained alive at last contact. Figure
2, A and E, indicates that within 18 months of death, the mean
FS z score was <-2.0, with a mean FS <31%. On the basis
of the separation in curves that starts at 36 months, depressed FS may
be a useful marker for increased mortality for up to 3 years before
death. In contrast, LV contractility (Figure 2D)
did not differ between survivors and nonsurvivors until 2 years before
death. LV mass (Figure 2, C and G) and end-systolic
dimension (Figure 2H) show a difference between survivors and
nonsurvivors >2 years before death, suggesting that these may be
long-term prognostic indicators. LV wall thickness (Figure 2, B
and F) shows a difference only 18 to 24 months before the final
echocardiogram. At the time of death, echocardiographic
measurements differed between survivors and nonsurvivors for FS (mean
z score, -1.11 and -2.32; mean FS, 32.3% and 29.8%), LV
mass (mean z score, 0.29 and 1.75; mean LV mass, 60.7 and
73.8 g), wall thickness (mean z score, -0.14 and 0.46;
mean wall thickness, 0.63 and 0.67 cm), end-diastolic
dimension (mean z score, 0.20 and 1.31; mean
end-diastolic dimension, 3.62 and 3.81 cm),
end-systolic dimension (mean z score, 0.70 and 2.25;
mean end systolic dimension, 2.44 and 2.74 cm), and
contractility (mean z score, -0.94 and
-1.88).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Baseline echocardiographic abnormalities in HIV-infected children were associated with cumulative all-cause mortality. In multivariable analyses, baseline depressed LV systolic performance and increased LV wall thickness made statistically significant contributions to the prediction of mortality after adjustment for immunodeficiency, HIV viral load, encephalopathy, and clinical center. We show that echocardiographic measurements (z scores) of LV structure and performance provide noninvasive, independent markers of disease and death in HIV-infected children that may be clinically useful.
Both contractility and FS were predictive of survival in univariable analyses. In multivariable analyses, however, FS was a more important predictor. This is not surprising, considering that FS represents the end products of multiple processes, including preload, afterload, heart rate, and contractility, all of which may be disturbed in these patients.
Differences in survival between clinical centers did not appear to be attributable to disease differences at baseline, because the center differences remained significant in multivariable models after disease variables were included. Therapeutic differences during follow-up or unidentified patient features we have not accounted for may be responsible. However, these survival differences among clinical centers may suggest differences in patient populations and not differences in the use of antiretroviral therapies, because >90% of the cohort received antiretroviral medications, and only a small subset took protease inhibitors.9
The study has some limitations. All-cause mortality was analyzed instead of cardiac death because of the low autopsy rate (19 of the 71 children). However, a report by the P2C2 HIV multidisciplinary mortality review committee found that among 93 group 1 and group 2 children who had an HIV-related death, 11 (11.8%) had chronic cardiac disease as the underlying cause of death, and 48 (51.6%) had evidence of chronic cardiac disease.11 The children in the sample were those who came in for clinical visits and whose parents or guardians consented to cardiopulmonary function testing, and so the children may not be representative of the more general population of HIV-infected children (eg, increased disease severity). Echocardiographic measurements from children with impaired growth rates similar to those of the HIV-infected children would have provided more appropriate control data than the healthy control children used in this study.
In summary, echocardiographic measures of LV structure and function are independent and potentially useful long-term and short-term predictors of overall mortality in HIV-infected children. The regular use of serial echocardiograms in this population may identify children at risk who may benefit from more careful examination and potentially effective interventions12 to alter the course of the disease. Future studies may determine whether treatment of baseline echocardiographic abnormalities associated with increased mortality is beneficial.
|
Acknowledgments |
|---|
This study was supported by the National Heart, Lung, and Blood Institute (NO1-HR-96037, NO1-HR-96038, NO1-HR-96039, NO1-HR-96040, NO1-HR-96041, NO1-HR-96042, and NO1-HR-96043) and in part by the National Institutes of Health (RR-00865, RR-00188, RR-02172, RR-00533, RR-00071, RR-00645, RR-00685, and RR-00043).
|
Footnotes |
|---|
Guest Editor for this article was David A. Sahn, MD, Oregon Health Sciences University, Portland.
Received August 5, 1999; revision received May 8, 2000; accepted May 8, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Lipshultz SE, Easley KA, Orav EJ, et al, for the Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. LV structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV multicenter study. Circulation. 1998;97:1246–56.
2. Starc TJ, Lipshultz SE, Kaplan S, et al, for the Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. Cardiac complications in children with human immunodeficiency virus infection. Pediatrics. 1999;104:2, e14. URL: http://www.pediatrics.org/cgi/content/full/104/2/e14.
3. Moorthy LN, Lipshultz SE. Cardiovascular monitoring of HIV-infected patients. In: Lipshultz SE, ed. Cardiology in AIDS. New York, NY: Chapman & Hall; 1998:345–84.
4. The P2C2 HIV Study Group. The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus (P2C2 HIV) infection study: design and methods. J Clin Epidemiol. 1996;49:1285–94.[Medline] [Order article via Infotrieve]
5. Devereux RB, Alonso DR, Lutas EM. Echocardiographic assessment of LV hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–8.[Medline] [Order article via Infotrieve]
6.
Dibley MJ, Goldsby JB, Staehling NW, et al.
Development of normalized curves for the international growth
reference: historical and technical considerations. Am J
Clin Nutr. 1987;46:736–48.
7. Cleveland RH, Schluchter M, Wood BP, et al, P2C2 HIV Study Group. Chest radiographic data acquisition and quality assurance in multicenter studies. Pediatr Radiol. 1997;27:880–887.[Medline] [Order article via Infotrieve]
8. Mofenson LM, Bethel J, Moye J, et al, for the National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. J Acquir Immune Defic Syndr. 1993;6:1103–13.
9.
Shearer WT, Lipshultz SE, Easley KA, et al, for the
Pediatric Pulmonary and Cardiovascular
Complications of Vertically Transmitted Human Immunodeficiency Virus
Study Group. Alterations in cardiac and pulmonary function in
pediatric rapid HIV-1 disease progressors. Pediatrics. 2000;105:1, e9. URL:
http://www.pediatrics.org/cgi/content/full/105/1/e9.
10. Centers for Disease Control and Prevention. Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43:1–19.
11. Langston C, Cooper ER, Goldfarb J, et al, for the P2C2 HIV Study Group. HIV-related mortality in infants and children: data from the P2C2 HIV study. Pediatrics. In press.
12.
Lipshultz SE, Orav EJ, Sanders SP, et al.
Immunoglobulins and LV structure and function in pediatric HIV
infection. Circulation. 1995;92:2220–2225.
This article has been cited by other articles:
 |
|
 |
|
  C. L. McDonald and J. R. Kaltman Cardiovascular disease in adult and pediatric HIV/AIDS. J. Am. Coll. Cardiol., September 22, 2009; 54(13): 1185 - 1188. [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Grinspoon, C. Grunfeld, D. P. Kotler, J. S. Currier, J. D. Lundgren, M. P. Dube, S. E. Lipshultz, P. Y. Hsue, K. Squires, M. Schambelan, et al. State of the Science Conference: Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS: Executive Summary Circulation, July 8, 2008; 118(2): 198 - 210. [Full Text] [PDF]
|
|
|
|
|
|
M. P. Dube, S. E. Lipshultz, C. J. Fichtenbaum, R. Greenberg, A. D. Schecter, S. D. Fisher, and for Working Group 3 Effects of HIV Infection and Antiretroviral Therapy on the Heart and Vasculature Circulation, July 8, 2008; 118(2): e36 - e40. [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Hruz, Q. Yan, H. Struthers, and P. Y. Jay HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy FASEB J, July 1, 2008; 22(7): 2161 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Hsue and D. D. Waters What a Cardiologist Needs to Know About Patients With Human Immunodeficiency Virus Infection Circulation, December 20, 2005; 112(25): 3947 - 3957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lipshultz and T. L. Miller Establishing norms for echocardiographic measurements of cardiovascular structures and function in children J Appl Physiol, August 1, 2005; 99(2): 386 - 388. [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lipshultz, S. R. Lipsitz, S. E. Sallan, V. M. Dalton, S. M. Mone, R. D. Gelber, and S. D. Colan Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia J. Clin. Oncol., April 20, 2005; 23(12): 2629 - 2636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Mone, M. W. Gillman, T. L. Miller, E. H. Herman, and S. E. Lipshultz Effects of Environmental Exposures on the Cardiovascular System: Prenatal Period Through Adolescence Pediatrics, April 1, 2004; 113(4/S1): 1058 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kan, Z. Xie, and M. S. Finkel p38 MAP kinase-mediated negative inotropic effect of HIV gp120 on cardiac myocytes Am J Physiol Cell Physiol, January 1, 2004; 286(1): C1 - C7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B D Prendergast HIV AND CARDIOVASCULAR MEDICINE Heart, July 1, 2003; 89(7): 793 - 800. [Full Text] [PDF]
|
|
|
|
|
|
I. Al-Attar, E. J. Orav, V. Exil, S. A. Vlach, and S. E. Lipshultz Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1598 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Nzuobontane, K N Blackett, and C Kuaban Cardiac involvement in HIV infected people in Yaounde, Cameroon Postgrad. Med. J., November 1, 2002; 78(925): 678 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. BARBARO, S. D FISHER, A. M PELLICELLI, and S. E LIPSHULTZ The expanding role of the cardiologist in the care of HIV infected patients Heart, October 1, 2001; 86(4): 365 - 367. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Lipshultz, K. A. Easley, E. J. Orav, S. Kaplan, T. J. Starc, J. T. Bricker, W. W. Lai, D. S. Moodie, G. Sopko, M. D. Schluchter, et al. Reliability of Multicenter Pediatric Echocardiographic Measurements of Left Ventricular Structure and Function: The Prospective P2C2 HIV Study Circulation, July 17, 2001; 104(3): 310 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Barbaro Cardiovascular manifestations of HIV infection J R Soc Med, January 8, 2001; 94(8): 384 - 390. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||